Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2009-02-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.01650-08PMID 19223634PMCID PMC2681549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection

  2007cited by this paper
• Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.

  2007cited by this paper
• Maturation inhibitors: a new therapeutic class targets the virus structure.

  2007cited by this paper
• 3-O-(3′,3′-Dimethysuccinyl) Betulinic Acid Inhibits Maturation of the Human Immunodeficiency Virus Type 1 Gag Precursor Assembled In Vitro

  2006cited by this paper
• In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)

  2006cited by this paper
• Determinants of activity of the HIV-1 maturation inhibitor PA-457.

  2006cited by this paper
• Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation

  2004cited by this paper
• PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

  2003influential reference

• Structural Basis for HIV-1 Maturation Inhibition by PF-46396 Determined by MAS NMR

  2025cites this paper
• Structural Basis for HIV-1 Maturation Inhibition by PF-46396 Determined by MAS NMR.

  2025cites this paper
• Distinct Target Site of Lenacapavir in Immature HIV-1 and Concurrent Binding with the Maturation Inhibitor Bevirimat.

  2025cites this paper
• A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication

  2024cites this paper
• Invention of VH-937, a Potent HIV-1 Maturation Inhibitor with the Potential for Infrequent Oral Dosing in Humans.

  2024cites this paper
• Structural insights into inhibitor mechanisms on immature HIV-1 Gag lattice revealed by high-resolution in situ single-particle cryo-EM

  2024cites this paper
• Turkish Plants, Including Quercetin and Oenothein B, Inhibit the HIV-1 Release and Accelerate Cell Apoptosis.

  2023cites this paper
• Selected Plant Triterpenoids and Their Derivatives as Antiviral Agents

  2023cites this paper
• Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232

  2023cites this paper
• Reflections on a 40-year career in drug design and discovery

  2023cites this paper
• Sub-stoichiometric Modulation of Viral Targets-Potent Antiviral Agents That Exploit Target Vulnerability.

  2023cites this paper
• Targeting the Virus Capsid as a Tool to Fight RNA Viruses

  2022cites this paper
• Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of Novel C-17 Amine Derivatives Based on GSK3640254 as HIV-1 Maturation Inhibitors with Broad Spectrum Activity.

  2022cites this paper
• New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?

  2022cites this paper
• The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.

  2022cites this paper
• Structural basis of HIV-1 maturation inhibitor binding and activity

  2022cites this paper
• Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition.

  2021cites this paper
• Betulinic Acid Decorated with Polar Groups and Blue Emitting BODIPY Dye: Synthesis, Cytotoxicity, Cell-Cycle Analysis and Anti-HIV Profiling

  2021cites this paper
• Preservation of HIV-1 Gag Helical Bundle Symmetry by Bevirimat Is Central to Maturation Inhibition

  2021cites this paper
• Highlights from the virtual conference on retroviruses and opportunistic infections (CROI) 2021: SARS-CoV-2 pathogenesis, new data about antiretroviral treatments, HIV-associated comorbidities, pediatrics and pregnancy

  2021cites this paper
• HIV-1 Maturation: Lessons Learned from Inhibitors

  2020cites this paper
• Recent Advances in HIV-1 Gag Inhibitor Design and Development

  2020cites this paper
• Recent advances in natural anti‐HIV triterpenoids and analogs

  2020cites this paper
• Novel Antiretroviral Agents

  2020cites this paper
• Betulin and its derivatives as novel compounds with different pharmacological effects.

  2019cites this paper
• STRUCTURE DETERMINATION OF HETEROGENEOUS BIOLOGICAL SPECIMENS IN CROWDED ENVIRONMENTS

  2019cites this paper
• Insight into the mechanism of action of EP‐39, a bevirimat derivative that inhibits HIV‐1 maturation

  2019cites this paper
• Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study

  2019cites this paper
• Second Generation Inhibitors of HIV-1 Maturation.

  2019cites this paper
• Maturation inhibitors facilitate virus assembly and release of HIV-1 capsid P224 mutant.

  2018cites this paper
• The KT Jeang Retrovirology prize 2018: Eric Freed

  2018influential citation
• The design, synthesis and structure-activity relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation.

  2018cites this paper
• MicroED Structure of the CTD-SP1 fragment of HIV-1 Gag with bound maturation inhibitor Bevirimat.

  2018cites this paper
• Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,1

  2018cites this paper
• Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

  2018cites this paper
• Resistance to Second-Generation HIV-1 Maturation Inhibitors

  2018cites this paper
• MicroED structures of HIV-1 Gag CTD-SP1 reveal binding interactions with the maturation inhibitor bevirimat

  2017cites this paper
• New Antiretrovirals for HIV and Antivirals for HBV

  2017cites this paper
• The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates

  2017cites this paper
• Quenching protein dynamics interferes with HIV capsid maturation

  2017cites this paper
• Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C

  2017cites this paper
• Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396

  2016cites this paper
• Identification of potent maturation inhibitors against HIV-1 clade C

  2016cites this paper
• Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity.

  2016cites this paper
• Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors

  2016cites this paper
• Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication

  2016cites this paper
• HIV-1 Capsid Inhibitors as Antiretroviral Agents.

  2016cites this paper
• Inhibitors of HIV-1 maturation: Development of structure-activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids.

  2016cites this paper
• C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors.

  2016cites this paper
• Maturation Inhibitor with Improved Potency, Anti-viral Spectrum and Gag Polymorphic

  2016cites this paper
• Mutational Immune Escape in HIV-1 Infection

  2015cites this paper
• The role of the HIV-1 protease substrate in therapy resistance

  2015cites this paper
• HIV-1 gag: an emerging target for antiretroviral therapy.

  2015cites this paper
• Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice

  2015cites this paper
• Protease-MediatedMaturation of HIV : Inhibitors of Protease and theMaturation Process

  2014influential citation
• Medications, Adherence and Interactions with Food

  2013cites this paper
• New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.

  2013cites this paper
• Virus Assembly as a Target for Antiretroviral Therapy

  2013cites this paper
• HIV Type 1 Gag as a Target for Antiviral Therapy

  2012cites this paper
• Determinants of the Development and Evolution of HIV-1 Drug Resistance

  2012cites this paper
• Targets for Inhibition of HIV Replication: Entry, Enzyme Action, Release and Maturation

  2012cites this paper
• Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.

  2012cites this paper
• Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process

  2012cites this paper
• Human Immunodeficiency Virus gag and protease: partners in resistance

  2012cites this paper
• Structural and Functional Insights into the HIV-1 Maturation Inhibitor Binding Pocket

  2012cites this paper
• HIV-1 Assembly, Release and Maturation

  2011cites this paper
• A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor Bevirimat

  2011cites this paper
• New approaches for antiviral targeting of HIV assembly.

  2011cites this paper
• A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor Bevirimat (cid:1)

  2011cites this paper
• Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers

  2011cites this paper
• The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles

  2011cites this paper
• HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat

  2011cites this paper
• Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat

  2010influential citation
• High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates

  2010cites this paper
• Molecular basis of human immunodeficiency virus drug resistance: an update.

  2010cites this paper
• Predicting Bevirimat resistance of HIV-1 from genotype

  2010influential citation
• Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database

  2010cites this paper
• Novel approaches to inhibiting HIV-1 replication.

  2010influential citation
• Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

  2010cites this paper
• Bioinformatical approaches to ranking of anti-HIV combination therapies and planning of treatment schedules

  2010cites this paper
• Researchin Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

  2010cites this paper
• In Vitro Selection of Clinically Relevant Bevirimat Resistance Mutations Revealed by “Deep” Sequencing of Serially Passaged, Quasispecies-Containing Recombinant HIV-1

  2010cites this paper
• New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation

  2009cites this paper
• Virus maturation as a new HIV-1 therapeutic target

  2009cites this paper
• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus

  2009cites this paper